Medicilon(SH:688202) Xin Lang Cai Jing·2025-11-05 03:13Company Overview - Shanghai Medicilon Inc. is located at 585 Chuan Da Road, Chuansha New Town, Pudong New District, Shanghai, and was established on February 2, 2004. The company was listed on November 5, 2019. Its main business involves providing comprehensive new drug research and development services for pharmaceutical companies and other new drug research institutions [1][2]. Financial Performance - For the period from January to September 2025, Medicilon achieved operating revenue of 843 million yuan, representing a year-on-year growth of 5.14%. The net profit attributable to the parent company was -29.68 million yuan, showing a year-on-year increase of 76.93% [2]. - Since its A-share listing, Medicilon has distributed a total of 158 million yuan in dividends, with 33.94 million yuan distributed over the past three years [3]. Stock Performance - As of November 5, Medicilon's stock price decreased by 2.01%, trading at 65.00 yuan per share, with a total market capitalization of 8.733 billion yuan. The stock has increased by 115.45% year-to-date, but has seen a decline of 7.22% over the last five trading days and 6.39% over the last 20 days [1]. - The company has appeared on the "龙虎榜" (Dragon and Tiger List) three times this year, with the most recent appearance on July 17, where it recorded a net purchase of 102 million yuan [1]. Shareholder Information - As of September 30, Medicilon had 16,500 shareholders, an increase of 27.83% from the previous period. The average number of circulating shares per person was 8,149, which decreased by 21.96% from the previous period [2]. Industry Classification - Medicilon belongs to the Shenwan industry classification of pharmaceutical biology, specifically in the medical services and medical research outsourcing sectors. It is associated with concepts such as raw materials, synthetic biology, CRO (Contract Research Organization), innovative drugs, and biopharmaceuticals [2].